二氯特诺 | 59-61-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 二氯特诺
• 中文别名: 二氯异丙苄醇
• 英文名称: dichloroisoproterenol
• 英文别名: 1 (3,4 dichlorophenyl) 2 isopropylaminoethanol；2-isopropylamino-1-(3,4-dichlorophenyl)ethanol；1-(3,4-dichlorophenyl)-2-(isopropylamino)ethan-1-ol；dichlorisoproterenol；dichloroisoprenaline；1-(3,4-dichlorophenyl)-2-(propan-2-ylamino)ethanol
• CAS: 59-61-0
• 化学式: C₁₁H₁₅Cl₂NO
• 分子量: 248.152
• InChiKey: VKMGSWIFEHZQRS-UHFFFAOYSA-N

物化性质

• 沸点：
  122.4°C (rough estimate)
• 密度：
  1.2061 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  二氯特诺 生成 (S)-Dichloroisoproterenol
  参考文献：
  名称：

  β-肾上腺素能阻断剂。3.普萘太洛，普萘洛尔和几种相关化合物的旋光异构体。

  摘要：

  DOI：

  10.1021/jm00312a003
• 作为产物：
  描述：

  在 ammonia borane 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以193 mg的产率得到二氯特诺
  参考文献：
  名称：

  由醛和异氰酸酯一锅法合成N取代的β-氨基醇

  摘要：

  已经开发出一种实用的两步法一锅法合成N-取代的β-氨基醇，该方法以醛和异氰酸酯为起始原料。该方法的特点是反应条件温和，范围广，对官能团的耐受性强。该协议基于较少见的中心碳-碳键断开连接，对涉及胺和各种碳亲电试剂（环氧化物，α-卤代酮，β-卤代醇）的传统方法进行了补充。如有关抗哮喘药沙丁胺醇的合成所示，可以从简单的结构单元中以简洁有效的方式制备药用相关产品。将合成物升级为对映选择性变体也是可行的。

  DOI：

  10.1002/chem.201500210
• 作为试剂：
  描述：

  N,N-二甲基甘氨酸 、 1-羟基苯并三唑 在 二氯特诺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 Dimethylamino-acetic acid benzotriazol-1-yl ester
  参考文献：
  名称：

  Antibacterial activity of glycine betaine analogues: involvement of osmoporters

  摘要：

  Glycine betaine (GB) analogues were obtained using solid phase organic synthesis and assayed for their toxic activity against 15 Gram positive and Gram negative bacteria. Four benzyl derivatives of GB were selected to determine their effect on bacterial growth. Bacteriostatic and lethal effects were observed for compound 1 and compound 2, respectively. The importation of the two GB analogues into bacterial cells appeared strictly dependent on the presence of the powerful betaine membrane osmoporters; their capacity to be amassed intracellularly at molar levels from extremely dilute Solutions might constitute a basis to design a new class of antimicrobial agents. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.02.045

文献信息

• NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：US20190023657A1

  公开（公告）日：2019-01-24

  The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like). Specifically, the present invention provides a compound or an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or the like, the compound represented by formula (I):

  本发明旨在提供一种具有TrkA抑制作用的化合物，其药学上可接受的盐或其溶剂合物，以及含有其作为活性成分的药物组合物，特别用于TrkA参与的疾病（疼痛、癌症、炎症/炎症性疾病、过敏疾病、皮肤疾病、神经退行性疾病、传染病、干燥综合征、子宫内膜异位症、肾脏疾病、骨质疏松症等）的预防和/或治疗剂。具体地，本发明提供一种化合物或其光学异构体，其药学上可接受的盐、其溶剂合物或类似物，该化合物由式（I）表示：
• Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
  申请人：——

  公开号：US20020143007A1

  公开（公告）日：2002-10-03

  The present invention describes novel nitrosated and/or nitrosylated &agr;-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and/or nitrosylated &agr;-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one &agr;-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.

  本发明描述了新型硝化和/或硝基化α-肾上腺素受体拮抗剂，以及包含至少一种硝化和/或硝基化α-肾上腺素受体拮抗剂的新型组合物，以及可选地包含一种或多种捐赠、转移或释放一氧化氮、提高内源性内皮衍生松弛因子水平、刺激内源性一氧化氮合成或是一氧化氮合成酶底物的化合物，和/或一种或多种血管活性药物。本发明还提供了包含至少一种α-肾上腺素受体拮抗剂和一种或多种捐赠、转移或释放一氧化氮、提高内源性内皮衍生松弛因子水平、刺激内源性一氧化氮合成或是一氧化氮合成酶底物，和/或一种或多种血管活性药物的新型组合物。本发明还提供了用于治疗或预防男性和女性的性功能障碍、增强男性和女性的性反应，以及治疗或预防良性前列腺增生、高血压、充血性心力衰竭、变异性（Printzmetal）心绞痛、青光眼、神经退行性疾病、血管痉挛性疾病、认知障碍、急迫性尿失禁或过度活跃膀胱，以及逆转麻醉状态的方法。
• PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS
  申请人：GANT Thomas G.

  公开号：US20080039473A1

  公开（公告）日：2008-02-14

  The present disclosure is directed to modulators of alpha-adrenergic receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the use of such compounds for the treatment and/or management of hypertension, cardiac failure, prostatitis, and benign prostatic hyperplasia, and any other condition in which it is beneficial to modulate an alpha-adrenergic receptor.

  本公开涉及α-肾上腺素受体的调节剂及其药用盐和前药，其化学合成，以及利用这些化合物治疗和/或管理高血压、心力衰竭、前列腺炎和良性前列腺增生，以及任何其他需要调节α-肾上腺素受体的情况。
• 制备如妥洛特罗、氯丙那林、二氯异丙肾上腺素和索他洛尔的β-芳基氨基醇类药物的方法
  申请人：北京化工大学

  公开号：CN110143886B

  公开（公告）日：2022-11-01

  本发明提供了一种制备如妥洛特罗、氯丙那林、二氯异丙肾上腺素和索他洛尔的β‑芳基氨基醇类药物的方法，所述β‑芳基氨基醇类药物具有式4所示的化学结构，其中，所述方法包括以下步骤：(1)式1所示的芳基乙酮与卤化试剂和亚砜反应，得到式2所示的芳基酮醛和/或式3所示的1,1‑二羟基芳基酮；(2)式2所示的芳基酮醛和/或式3所示的1,1‑二羟基芳基酮与化学式为R1‑NH2的胺类化合物进行亲核加成反应和还原剂存在下的还原胺化反应，得到β‑芳基氨基醇类药物；
• NOVEL PYRAZOLE DERIVATIVE
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：US20140378447A1

  公开（公告）日：2014-12-25

  It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.

  已经有人希望开发一种药物组合物，用于预防和/或治疗与PDE10相关的各种疾病（例如精神障碍和神经退行性疾病）。本发明提供：具有PDE10抑制作用的化合物，特别是具有以下式（I）所代表的4-杂环芳基吡唑-5-羧酰胺结构的化合物，或其药学上可接受的盐，或其溶剂化物；包含作为活性成分的化合物，或其药学上可接受的盐，或其溶剂化物的药物组合物；以及化合物的医学用途，或其药学上可接受的盐，或其溶剂化物。

表征谱图